These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

338 related items for PubMed ID: 8047080

  • 21. Prolonged survival in patients with beta-thalassemia major treated with deferoxamine.
    Ehlers KH, Giardina PJ, Lesser ML, Engle MA, Hilgartner MW.
    J Pediatr; 1991 Apr; 118(4 Pt 1):540-5. PubMed ID: 2007928
    [Abstract] [Full Text] [Related]

  • 22. Pulmonary function abnormalities in thalassemia major and the role of iron overload.
    Factor JM, Pottipati SR, Rappoport I, Rosner IK, Lesser ML, Giardina PJ.
    Am J Respir Crit Care Med; 1994 Jun; 149(6):1570-4. PubMed ID: 8004315
    [Abstract] [Full Text] [Related]

  • 23. Magnetic-susceptibility measurement of human iron stores.
    Brittenham GM, Farrell DE, Harris JW, Feldman ES, Danish EH, Muir WA, Tripp JH, Bellon EM.
    N Engl J Med; 1982 Dec 30; 307(27):1671-5. PubMed ID: 7144866
    [Abstract] [Full Text] [Related]

  • 24. Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major.
    Wolfe L, Olivieri N, Sallan D, Colan S, Rose V, Propper R, Freedman MH, Nathan DG.
    N Engl J Med; 1985 Jun 20; 312(25):1600-3. PubMed ID: 4000198
    [Abstract] [Full Text] [Related]

  • 25. Impact of magnetic resonance imaging on cardiac mortality in thalassemia major.
    Chouliaras G, Berdoukas V, Ladis V, Kattamis A, Chatziliami A, Fragodimitri C, Karabatsos F, Youssef J, Karagiorga-Lagana M.
    J Magn Reson Imaging; 2011 Jul 20; 34(1):56-9. PubMed ID: 21608067
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Clinical studies on iron chelation in patients with thalassemia major.
    Freedman MH, Olivieri N, Benson L, Liu P, McClelland R, St Louis P, Templeton D, Koren G.
    Haematologica; 1990 Jul 20; 75 Suppl 5():74-83. PubMed ID: 2086384
    [No Abstract] [Full Text] [Related]

  • 30. Clinicopathological and radiological study of Egyptian β-thalassemia intermedia and β-thalassemia major patients: relation to complications and response to therapy.
    Mokhtar GM, Tantawy AA, Adly AA, Ismail EA.
    Hemoglobin; 2011 Jul 20; 35(4):382-405. PubMed ID: 21797705
    [Abstract] [Full Text] [Related]

  • 31. The importance of spleen, spleen iron, and splenectomy for determining total body iron load, ferrikinetics, and iron toxicity in thalassemia major patients.
    Kolnagou A, Michaelides Y, Kontoghiorghe CN, Kontoghiorghes GJ.
    Toxicol Mech Methods; 2013 Jan 20; 23(1):34-41. PubMed ID: 23039902
    [Abstract] [Full Text] [Related]

  • 32. Morbidities and mortality in transfusion-dependent Beta-thalassemia patients (single-center experience).
    Mokhtar GM, Gadallah M, El Sherif NH, Ali HT.
    Pediatr Hematol Oncol; 2013 Mar 20; 30(2):93-103. PubMed ID: 23301991
    [Abstract] [Full Text] [Related]

  • 33. Therapy for beta-thalassemia--a paradigm for the treatment of genetic disorders.
    Dover GJ, Valle D.
    N Engl J Med; 1994 Sep 01; 331(9):609-10. PubMed ID: 8047089
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Deferoxamine-induced platyspondyly in hypertransfused thalassemic patients.
    Levin TL, Sheth S, Berdon WE, Ruzal-Shapiro C, Piomelli S.
    Pediatr Radiol; 1995 Nov 01; 25 Suppl 1():S122-4. PubMed ID: 8577502
    [Abstract] [Full Text] [Related]

  • 36. Clinical consequences of acquired transfusional iron overload in adults.
    Schafer AI, Cheron RG, Dluhy R, Cooper B, Gleason RE, Soeldner JS, Bunn HF.
    N Engl J Med; 1981 Feb 05; 304(6):319-24. PubMed ID: 6777701
    [Abstract] [Full Text] [Related]

  • 37. The impact of neocyte transfusion in the management of thalassaemia.
    Spanos T, Ladis V, Palamidou F, Papassotiriou I, Banagi A, Premetis E, Kattamis C.
    Vox Sang; 1996 Feb 05; 70(4):217-23. PubMed ID: 9123927
    [Abstract] [Full Text] [Related]

  • 38. Efficacy of hydroxyurea in providing transfusion independence in β-thalassemia.
    Ansari SH, Shamsi TS, Ashraf M, Perveen K, Farzana T, Bohray M, Erum S, Mehboob T.
    J Pediatr Hematol Oncol; 2011 Jul 05; 33(5):339-43. PubMed ID: 21602718
    [Abstract] [Full Text] [Related]

  • 39. [The evolutionary effects of therapy on the skeletal lesions in beta-thalassemia].
    Orzincolo C, Castaldi G, Bariani L, Scutellari PN.
    Radiol Med; 1994 Apr 05; 87(4):381-8. PubMed ID: 8190918
    [Abstract] [Full Text] [Related]

  • 40. Use of deferoxamine (DFO) in transfusion-dependent β-thalassemia during pregnancy: A retrospective study.
    Piccioni MG, Capone C, Vena F, Del Negro V, Schiavi MC, D'Ambrosio V, Giancotti A, Smacchia MP, Brunelli R.
    Taiwan J Obstet Gynecol; 2020 Jan 05; 59(1):120-122. PubMed ID: 32039778
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.